| Company Name | Fiscal Year | EPS (Actual) | EPS (Estimated) | Revenue (Actual) | Revenue (Estimated) | Exchange | |||
|---|---|---|---|---|---|---|---|---|---|
| Loading past events... | |||||||||
|
Thursday - Aug 28, 2014 |
|||||||||
| Q2 FY14 | $0.83 | $0.83 | $4.72B | $4.72B |
NYSE |
||||
|
Coty
COTY
|
Q4 FY14 | $0.03 | $0.05 | $1.04B | $1.74B |
NYSE |
|||
| Q3 FY14 | $0.13 | $0.11 | $1.27B | $1.03B |
NASDAQ |
||||
|
Genesco
GCO
|
Q2 FY15 | $0.34 | $0.55 | $615.47M | $995.66M |
NYSE |
|||
Abercrombie & Fitch
ANF
|
- | $0.19 | $0.11 | $890.61M | $515.61M |
NYSE |
|||
|
Splunk
SPLK
|
Q2 FY15 | $0.01 | - | $101.55M | $203.09M |
NASDAQ |
|||
|
Trupanion
TRUP
|
- | -$2.25 | -$0.31 | $25.64M | $152.59M |
NASDAQ |
|||
|
Destination XL Group
DXLG
|
Q2 FY14 | -$0.05 | -$0.04 | $103.71M | $83.36M |
NASDAQ |
|||
|
Veeva Systems Inc.
VEEV
|
Q2 FY15 | $0.09 | $0.07 | $75.66M | $58.85M |
NYSE |
|||
|
DiaMedica Therapeutics
DMAC
|
- | -$0.40 | -$0.60 | - | - |
NASDAQ |
|||
